Several studies have shown the downregulation of PPARγ and PGC-1α in various cell types obtained from FRDA patients and animal models (Coppola et al., 2009; Marmolino and Acquaviva, 2009), a situation suggesting the likely importance of pioglitazone in FRDA therapy. Here, PPARGC1A is linked to Friedreich ataxia.